Kevin Geoffrey Birkett - 17 Feb 2022 Form 4 Insider Report for Ensysce Biosciences, Inc. (ENSC)

Role: Chief Commercial Officer
Signature: /s/ Kevin Geoffrey Birkett
Issuer symbol: ENSC
Transactions as of: 17 Feb 2022
Transactions value $: $0
Form type: 4
Filing time: 24 Feb 2022, 18:03:36
Previous filing: 02 Jul 2021
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ENSC	Stock Option	Award		+50K			50K	17 Feb 2022	Common Stock	50K	$1.40	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On February 17, 2022, Mr. Birkett was granted an option (the "Stock Option") to purchase 50,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter.

Content

On February 17, 2022, Mr. Birkett was granted an option (the "Stock Option") to purchase 50,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter.